Across TCGA pan-cancer cohorts, GSTM2 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated GSTM2 data layer compared with 1 for mutation status and 5 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher GSTM2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated GSTM2 expression acts as an unfavorable survival marker, although some lineages such as BRCA and LUAD show a favorable association.
BRCA, LUAD, and UVM are the cancer types where GSTM2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.